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Abstract
Background: Both obesity and over-expression of HER II are associated with poor prognosis of
breast cancer. In vitro experiments suggest that anti-tumour activity of the anti-obesity drug
Orlistat is likely to be due to transcriptional suppression of HER II expression. The overexpression
of HER II is also positively correlated with other markers of prognosis of breast cancer such as
cathepsin expression.
Hypothesis: The hypothesis we tested was that the obese women with breast cancer might over-
express HER II more often than their lean counterparts to account for the poor prognosis.
Patients and methods: One hundred consecutive patients were included in this study. Their
body mass indexes were correlated with overexpression of HER II.
Results: There was also no association between oestrogen or progesterone receptor positivity
and obesity or HER II over expression in premenopausal or post-menopausal women with breast
cancer.
Conclusion: The present study demonstrated that the poor outcome of breast cancer in obese
patients is not due to over expression of HER II.
Introduction
Obesity leads to poor prognosis in women diagnosed
with breast cancer even in early stage disease as shown in
systematic literature reviews, several large-scale cohort
studies and critical reviews such as the Nurse's Health
study and cancer prevention study II [1-9]. The women
with breast cancer in the highest quartile of BMI are 2.5
times as likely to die of their disease within 5 years of diag-
nosis compared with women in the lowest quartile of BMI
[10].
Recent in vitro experiments suggest that anti-obesity
agents Orlistat may have anti-tumour activity which is
likely to be due to transcriptional suppression of HER II
expression [11]. Orlistat, has potent anti-proliferate and
apoptotic effects on breast cancer cells through its ability
to block the lipogenic activity of Fatty Acid Synthetase
[12]. In vitro experiments also suggest that essential fatty
acids such as omega-3 suppress overexpression of HER II
at the transcriptional level, which, in turn, interacts syner-
gistically with anti-HER II agents such as Traztuzumab
[13]. Traztuzumab is a humanized monoclonal antibody
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directed against the extracellular domain of the tyrosine
kinase receptor HER II. Abnormalities of fatty acid metab-
olism in the development of breast cancer are well docu-
mented and the association between Fatty acid
metabolism and HER II antagonists is being discovered
REF [14]. Therefore, Obesity may be the missing link
between the development of breast cancer and over-
expression of HER II because of its effect on essential fatty
acids These findings suggest a possible association
between obesity, abnormal lipid metabolism and an over-
expression of HER II.
Over-expression of HER II is also associated with a poor
prognosis of breast cancer as HER II over-expression playS
an important role in the development, aggressive behav-
iour of breast cancer. Overexpression of HER II has been
associated with other markers of poor prognosis of breast
cancer such as cathepsin D [15].
The hypothesis we tested was that the obese women with
breast cancer over-express HER II more often than their
lean counterparts to account for the poor prognosis in
obese women.
Patients and methods
One hundred consecutive patients were included in this
study. Their height, weight and body mass index were cor-
related with overexpression of HER II.
Laboratory methods
The criteria of HER II over expression were used as per Pan
Birmingham Protocol. The HER II over expression was
measured by immunohistochemistry (DAKO)®. The bor-
derline cases were tested with fluorescence in situ hybrid-
isation (Abbott Path Vision)®.
Statistical methods
Using the chi(2)-test, relationships were determined
between marker labelling and histological type of cancer,
tumour grade, tumour size, axillary lymph node status
and age of patient. A p value below 0.05 was considered
significant.
Body mass index according to HER II Overexpression Figure 1
Body mass index according to HER II Overexpression. Horizontal lines are mean.
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Results
All results are summarised in table 1. Using the BMI cate-
gories of less than 25, 25–30, 30–35 and more than 35 kg/
m2 there is no significant trend in the proportions who are
HER positive or negative within these categories Figure 1.
There was also no association between oestrogen or pro-
gesterone receptor positivity and obesity or HER II over
expression in premenopausal or post-menopausal
women with breast cancer, Figure 1 and Table 1.
Discussion
Obesity is associated with poor prognosis of breast cancer.
The exact mechanism by which obesity affects the out-
come of breast cancer is not fully understood. HER II over-
expression is associated with poor prognosis of breast
caner. The present study demonstrated that the poor out-
come of breast cancer in obese patients was not due to
overexpression of HER II. The present study is in concord-
ance with another small-scale study that showed no asso-
ciation obesity and erbB-2 expression without the use of
Fluorescence in-situ hybridisation (FISH) [16]. The
present study confirmed that even after FISH analysis
there seem to be no association between obesity and HER
II expression. These are small-scale studies, and warrant
larger scale research.
The relationship between obesity and steroid hormone
receptors is complex and controversial. Several relation-
ships have been reported and refuted. Our study is in con-
cordance with other reports, which show no reliable
association between steroid hormone receptor and obes-
ity in breast cancer patients.
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Table 1: The association between obesity, hormone receptor status and HER II overexpression
BMI < 35 BMI > 35 P value BMI < 30 BMI > 30 P value
HER 33/88 (38%) 4/6 (67%) 0.21 27/66 (41%) 10/28 (36%) 0.82
ER 53/85 (62%) 4/6 (67%) 1 38/65 (58%) 19/26 (73%) 0.24
PgR 43/74 (58%) 1/2 (50%) 1 33/58 (57%) 11/18 (61%) 0.79